Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia Refractory
DRUG: Venetoclax|DRUG: 6-mercaptopurine
Clinical response, Objective response rate, at 2 months|Clinical response, Objective response rate, at 6 months|Clinical response, Objective response rate, at 2 years
Non-commercial, open-label interventional phase Ib study. The aim of the study is to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.